COVID Vaccine Update: Sputnik V Is 91.4% Effective, New Coronavirus Variant May Not Affect Shots | Photo credit: iStock Images
New Delhi: The light at the end of the tunnel when it comes to the COVID-19 pandemic can be seen with various vaccines receiving approval for emergency use in many countries. Leading candidates for COVID-19 vaccine include, among others, Moderna candidates, Pfizer BioNTech, Sputnik V, Oxford-AstraZenenca’s COVID vaccine. Covaxin, the vaccine candidate grown in India, also looks promising.
Check out the latest updates on coronavirus vaccine candidates from around the world. A new variant of the novel coronavirus has also been reported in England and some researchers are concerned if it will negatively impact ongoing vaccinations.
Sputnik V 91.4% effective during phase 3 tests
According to recent reports, Sputnik V, Russia’s leading COVID-19 vaccine candidate, showed 91.4% effectiveness in preventing COVID-19, during Phase 3 trials. Sputnik V was jointly developed by the Gamaleya National Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF).
“According to a joint statement, the Gamaleya Center and RDIF have announced efficacy of more than 90%, as demonstrated by the final checkpoint data analysis of the largest double-blind, randomized, post-registration Phase 3 clinical trials. and placebo-controlled of the Sputnik V vaccine against the new coronavirus “, reported the news agency ANI.
A new variant of the novel coronavirus may not affect current vaccines
A new variant of the novel coronavirus has been reported in parts of England. More than 1,000 people have been infected with this new variant of the virus so far. While a WHO team is examining the new variant, the researchers are confident it will not impact the vaccines that have been developed so far.
WHO said there is no evidence to suggest the mutation will impact the effectiveness of vaccines against the disease.
Even earlier, when new strains of the novel coronavirus were reported in various places around the world, experts had said the chances of the new variants affecting the vaccine’s effectiveness were limited. Experts also said you may not need more than one vaccine for the virus, regardless of variants.